Feature

Immunotherapy moves into the breast cancer landscape


 

At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

BOLERO-1: Everolimus shows strong signal in HER2+ advanced breast cancer
Breast Cancer ICYMI
Concomitant depression in breast cancer survivors doubles health care costs
Breast Cancer ICYMI
Accelerated partial breast irradiation effective
Breast Cancer ICYMI
International study characterizes male breast cancer
Breast Cancer ICYMI
Adjuvant paclitaxel plus trastuzumab benefits patients with early breast cancer
Breast Cancer ICYMI
Breast cancer mortality down, but racial differences persist
Breast Cancer ICYMI
Aromatase inhibitors linked to dental problems
Breast Cancer ICYMI
Adjuvant taxane benefit for breast cancer varies by subtype
Breast Cancer ICYMI
Big savings achievable with evidence-based radiotherapy for breast Ca
Breast Cancer ICYMI
Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer
Breast Cancer ICYMI